PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome - PubMed (original) (raw)

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Jacquelot N, et al. Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2. Nat Commun. 2017. PMID: 28928380 Free PMC article.

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells.

Caraban BM, Matei E, Cozaru GC, Aşchie M, Deacu M, Enciu M, Bălţătescu GI, Chisoi A, Dobrin N, Petcu L, Gheorghe E, Hangan LT, Roșu MC, Orasanu CI, Nicolau AA. Caraban BM, et al. J Pers Med. 2023 Jan 27;13(2):221. doi: 10.3390/jpm13020221. J Pers Med. 2023. PMID: 36836455 Free PMC article.